Sumitomo Pharma Co., Ltd. SMDPY
12.47 USD -1.04 (-7.67%)
At closeNov 3, 2026, 4:00 PM EST
12.75 Day range 12.75
7.84 52-week range 24.48
- YTD
- +8.86%
- 1 year
- +8.86%
- Market cap
- 5.59B
- EPS (ttm)
- 0.65
- P/E ratio
- 19.18
- YTD return
- +8.86%
- 1-year return
- +8.86%
- Volume
- 500
- Avg volume
- 744
- Open
- 12.75
- Previous close
- 13.50
- Day's range
- 12.75 – 12.75
- 52-week range
- 7.84 – 24.48
2Y +8.38 (+191.76%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2026 | Mar 31, 2026 | — | -0.01302 | — | — |
| Jan 29, 2026 | Dec 31, 2025 | — | 0.1442 | — | — |
| Oct 28, 2025 | Sep 30, 2025 | — | 1.50 | — | — |
| Aug 4, 2025 | Jun 30, 2025 | — | 0.1948 | — | — |
| May 12, 2025 | Mar 31, 2025 | — | 0.0418 | — | — |
| Jan 29, 2025 | Dec 31, 2024 | — | 0.856 | — | — |
News
Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting 
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa 
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia 
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript 
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Your note
Sign in to keep a note on SMDPY — it syncs with the Stock Master app.